Drawing for INDUS PHARMACEUTICALS

USPTO serial 78596173

INDUS PHARMACEUTICALS

Reviewed by CopyMark Law Group

Reg. 3674488Status 800Registered
Filing date
Status date
Registration date
Aug 25, 2009
Examiner
BHANOT, KAPIL KUMAR
Law office
GENERIC WEB UPDATE

What this means

Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection. Calendar the next Section 8 and 9 deadline in 10 years and maintain monitoring.

Status 800: Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection.

Need help with INDUS PHARMACEUTICALS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

H. Straat Tenney

H. Straat Tenney Locke Lord LLPChurch Street Station, P.O. Box 1470New York, NY 10008-1470UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
042pharmaceutical drug development services of pharmaceutical products intended for the treatment of infectious diseases, namely, bacterial, fungal, parasitic and viral infections; pharmaceutical drug development services of pharmaceutical products intended for the treatment of neoplastic disorders, namely, hematologic cancer disorders and solid tumors; pharmaceutical drug development services of pharmaceutical products intended for the treatment of autoimmune disorders, namely, diabetes, arthritis, psoriasis, bone marrow and organ transplantation and immunosuppression; pharmaceutical drug development services of pharmaceutical products intended for the treatment of metabolic disorders, namely, obesity and atherosclerosis; pharmaceutical drug development services of pharmaceutical products intended for the treatment of cardiovascular disorders, namely, hypertension, congestive heart failure, myocardial infarction, angina and vascular diseases; pharmaceutical drug development services of pharmaceutical products intended for the treatment of renal disorders, namely, acute and chronic renal failure and urinary disorders affecting renal conservation of water; pharmaceutical drug development services of pharmaceutical products intended for the treatment of central nervous system disorders, namely, analgesia, anesthesia, hypnotics, sedatives, anxiety, psychosis, depression, mania, epilepsies, migraine, neurodegeneration, and drug addiction; pharmaceutical drug development services of pharmaceutical products intended for the treatment of inflammatory disorders, namely, asthma, gout, inflammatory bowel disease, and rheumatoid arthritis; pharmaceutical drug development services of pharmaceutical products intended for the treatment of gastrointestinal disorders, namely, ulcers, emesis, diarrhea, and irritable bowel syndrome; pharmaceutical drug development services of pharmaceutical products intended for the treatment of hormonal disorders affecting the thyroid, estrogens, progestins, androgens, glucocorticoids, insulin and glucose regulation; pharmaceutical drug development services of pharmaceutical products intended for the treatment of calcification and bone turnover; and pharmaceutical drug development services of pharmaceutical products intended for the treatment of dermatological and opthalmological disordersACTIVEMar 31, 2006

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 3, 2019NA89NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED—
Oct 3, 2019RNL1REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active.
Oct 3, 201989AGREGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTEDThe USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary.
Oct 3, 2019APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Aug 23, 2019E89RTEAS SECTION 8 & 9 RECEIVED—
Aug 25, 2018REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Jan 22, 2016TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Sep 25, 2015NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Sep 25, 2015C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Sep 25, 2015APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Aug 21, 2015E815TEAS SECTION 8 & 15 RECEIVED—
Aug 25, 2009R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 21, 2009REGVLAW OFFICE REGISTRATION REVIEW COMPLETED—
Jul 21, 2009ALIEASSIGNED TO LIE—
Jul 13, 2009CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Jul 9, 2009SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jul 9, 2009AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jun 15, 2009EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Jun 13, 2009IUAFUSE AMENDMENT FILED—
Dec 10, 2008EX5GSOU EXTENSION 5 GRANTED—
Dec 10, 2008EXT5SOU EXTENSION 5 FILED—
Dec 10, 2008EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 12, 2008EX4GSOU EXTENSION 4 GRANTED—
Jun 12, 2008EXT4SOU EXTENSION 4 FILED—
Jun 12, 2008EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 8, 2008DOCKASSIGNED TO EXAMINER—
Dec 13, 2007EX3GSOU EXTENSION 3 GRANTED—
Dec 13, 2007EXT3SOU EXTENSION 3 FILED—
Dec 13, 2007EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 13, 2007EX2GSOU EXTENSION 2 GRANTED—
Jun 13, 2007EXT2SOU EXTENSION 2 FILED—
Jun 13, 2007EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 13, 2006EX1GSOU EXTENSION 1 GRANTED—
Dec 13, 2006EXT1SOU EXTENSION 1 FILED—
Dec 13, 2006EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 13, 2006NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 21, 2006PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 1, 2006NPUBNOTICE OF PUBLICATION—
Feb 3, 2006PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Dec 2, 2005ALIEASSIGNED TO LIE—
Nov 29, 2005CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 29, 2005GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 29, 2005CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 23, 2005TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 17, 2005CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 17, 2005TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 25, 2005GEAPEXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Oct 25, 2005CPEAEXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED—
Oct 22, 2005DOCKASSIGNED TO EXAMINER—
Apr 1, 2005NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance